Grace Halsey

Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.

Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.

TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.

TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.

TMS 2025. University of Toronto professor Dr Marla Shapiro explains why perimenopause is unpredictable, including age of onset, duration, and symptoms.

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.

Vaccine-preventable diseases claim up to 50,000 adult lives each year in the US. Click through this compact reminder of recommended catch up shots for your patient panel.

Undertreated acute pain can lead to life-long chronic pain but there are still few effective opioid-sparing options. A new review reinforces the persistent safety issues.

The survey of more than 19,000 American women found low energy and sleep problems more disruptive than VMS and that Autumn is the most symptomatic season.

Obesity rates in states where it has leveled at 35% decreased for the first time but report authors warn the progress is limited and at risk due to federal budget cuts.

The Frist Clinic clinician said that technical difficulty is not impeding CGM uptake in primary care. "The real limitation is they just haven't done it before."

The Menopause Society 2025 Annual Meeting, Oct 21-25, in Orlando, will focus on optimizing women's health and longevity at menopause and beyond. Highlights here.

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.

A large Australian study found that training primary care physicians increased long-term LARC use, reduced unintended pregnancies, and improved reproductive health outcomes.

Shared decision-making for COVID-19 vaccines will widen disparities, said Moore, as those already skeptical or with limited access will likely opt out.

An 18-year multicohort study found that smokers who quit even in later life showed 20% slower memory decline vs those who continued to smoke.

Managing post–MI distress is no longer optional—it’s essential to comprehensive cardiac recovery, according to a new AHA statement.

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.

Based on the PREVENT algorithm's estimates of 10-year ASCVD risk, 4.2 million adults may need to be reevaluated for aspirin discontinuation, authors reported.

Roche's Elecsys pTau181 test has a 97.9% negative predictive value to rule out amyloid pathology, which will improve referral decisions and expedite treatment.

New global WHO data show escalating resistance in key bacterial pathogens, threatening frontline antibiotics and narrowing treatment options worldwide.

Vega considers the impact of recent changes in immunization policy on trust not just among patients but among clinicians as well. It all threatens good patient care, he said.

Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.

Clinical and real-world data are on deck for lumateperone, seltorexant, and esketamine to treat major depressive disorder and treatment-resistant depression.

OLPs did not affect migraine frequency but did subjectively improve QoL, with authors noting they may have a role as a supportive treatment option for select patients.

Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.

Post-Dobbs data reveal medication abortion now represents nearly two-thirds of all US abortions. Wetterer reviews trends and implications.

As dementia care grows more complex and more promising, the role for front-line clinicians is becoming more nuanced and more essential.